Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain
Information source: University of Michigan Cancer Center
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Cancer
Intervention: Duloxetine (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Michigan Cancer Center Official(s) and/or principal investigator(s): Norah L Henry, MD, PhD, Principal Investigator, Affiliation: University of Michigan
Summary
Many women with breast cancer who are treated with aromatase inhibitor medications develop
aches and pains during treatment, and some develop numbness and tingling in their hands and
feet. Some examples of aromatase inhibitor medications include anastrozole (Arimidex),
exemestane (Aromasin), and letrozole (Femara). Frequently, pain medications do not work very
well to relieve the pain. Duloxetine (Cymbalta) is a medication that was originally
developed to treat depression. It has also been found to relieve pain that occurs in people
with diabetes, fibromyalgia, arthritis, and other painful conditions. In this study we are
testing to see if duloxetine will help treat the pain that can occur in women treated with
aromatase inhibitors.
Clinical Details
Official title: UMCC 2008.62: Prospective Pilot Study Evaluating the Use of Duloxetine for Treatment of Aromatase Inhibitor-associated Musculoskeletal Symptoms in Breast Cancer Patients
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Percentage of Patients Who Experience 30% Reduction in Average Pain Score From Baseline to 8 Weeks Due to Duloxetine Therapy.
Secondary outcome: Decrease in Average Pain With 8 Weeks of Duloxetine Therapy. (Sustained)
Detailed description:
Aromatase inhibitor (AI) therapy is commonly used for treatment of postmenopausal women with
hormone receptor-positive breast cancer. The most common toxicities are arthralgias and
myalgias, which can be difficult to manage and necessitate discontinuation of therapy in up
to 10% of patients. One potential interventional approach is with a pharmaceutical agent
such as duloxetine, which has been shown to be effective for treatment of other types of
chronic pain, including fibromyalgia and diabetic neuropathic pain.
The primary objective of this pilot study is to determine the proportion of breast cancer
patients with AI-associated musculoskeletal symptoms who experience a 30% reduction in
average pain score from baseline to 8 weeks due to duloxetine treatment. Participants will
be treated with duloxetine for 8 weeks. Questionnaires to evaluate pain, functional status,
depression, menopausal symptoms, and sleep difficulties will be administered at baseline and
after 2, 4, 6, and 8 weeks of therapy. In addition, 10 milliliters blood of will be drawn
from the subjects at baseline for future pharmacogenetic evaluation. If the results of this
pilot study suggest that the efficacy of duloxetine therapy is greater than that expected
from placebo based on historical controls, then these data will be used to design future
prospective, placebo-controlled, randomized trials of treatment with duloxetine in this
patient population.
Eligibility
Minimum age: 21 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Female;
- Histologically proven stage 0-III invasive carcinoma of the breast that is ER and/or
PR positive by immunohistochemical staining, who are receiving a standard dose of
aromatase inhibitor (AI) therapy (letrozole 2. 5mg once daily or exemestane 25mg once
daily or anastrozole 1mg once daily). Women with oligometastatic disease may be
included at the discretion of the principal investigator. Surgical resection,
chemotherapy, and radiation therapy must have been completed at the time of study
enrollment, with the exception of trastuzumab;
- AI therapy has been ongoing for ≥ 2 weeks and treatment is expected to continue;
- AI-associated musculoskeletal symptoms, defined as:
- Grade 1 or higher musculoskeletal pain that developed or worsened (6 or 7 on
CGICS) during AI therapy or
- Grade 1 or higher sensory neuropathy that developed or worsened (6 or 7 on
CGICS) during AI therapy;
- Average pain of ≥4 on the 11-point Likert scale of question #5 of the Brief Pain
Inventory;
- ECOG performance status 0-2;
- Willing and able to sign an informed consent document.
Exclusion Criteria:
- Known hypersensitivity to duloxetine or any of the inactive ingredients;
- New musculoskeletal pain that is due specifically to fracture or traumatic injury;
- Treatment with monoamine oxidase inhibitors (MAO-I) within 14 days of enrollment;
- Concurrent treatment with phenothiazines (including thioridazine), propafenone,
flecainide, triptans, MAO-Is, SSRIs, SNRIs, or tricyclic antidepressants;
- Currently primary psychiatric diagnosis (schizophrenia, psychosis) or suicidal
ideation, history of bipolar disorder, or seizure disorder;
- Chronic liver disease, end stage renal disease, or creatinine clearance < 30 mL/min
as defined by the Cockroft-Gault equation;
- Uncontrolled narrow-angle glaucoma or clinically significant coagulation disorder;
- Pregnant or breast feeding;
- History of alcohol or other substance abuse or dependence within the year prior to
enrollment;
- Serious or unstable medical condition that could likely lead to hospitalization
during the course of the study or compromise study participation.
Locations and Contacts
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109-0944, United States
Additional Information
Starting date: October 2008
Last updated: July 26, 2013
|